Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer

Bruton’s tyrosine kinase (BTK) inhibitors, drugs utilized in cancer, are being repurposed for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (COVID-19). Recently, BTK inhibitors acalabrutinib and ibrutinib have been found to protect against pulmonary injury in a small group of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Benner, Brooke, Carson, William E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805262/
https://www.ncbi.nlm.nih.gov/pubmed/33441177
http://dx.doi.org/10.1186/s13045-020-00999-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805262/
https://www.ncbi.nlm.nih.gov/pubmed/33441177
http://dx.doi.org/10.1186/s13045-020-00999-8

Ejemplares similares